Serial Ketamine Infusions for Treatment-Resistant Bipolar Depression: A Randomized Clinical Trial

This double-blind randomised midazolam-controlled clinical trial (n=68) found that four intravenous ketamine infusions (35–53 mg/70 kg) over two weeks reduced depressive symptoms more than midazolam in adults with treatment-resistant bipolar I or II depression. No mania, hypomania, psychosis, or suicide attempts occurred, although one participant in each group developed subthreshold mixed features.